PSQ Holdingsの空売り状況は、投資家がPSQ Holdingsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

PSQ Holdings (NYSE:PSQH) 株価情報, 空売り情報

PSQ Holdings

PSQ Holdings Inc operates the website and mobile application named as PublicSq. It is an app and website that connects freedom-loving Americans to high-quality businesses that share values, both online and in local communities. It has three reportable segments comprised of Marketplace; which includes a marketplace platform to access consumers that are drawn to patriotic values and the revenue is generated in the form of advertising and eCommerce transactions, and Brands segment in which through its wholly-owned brand, the company generates revenue from online sales of diapers and wipes and third financial technology which assists consumers, lenders, and retailers in offering point-of-sale financing products.

PSQ Holdings Inc

PSQ Holdings, Inc. Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share

Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNM#NASDAQ">CTNM</a>) with a Overweight and lowers the price target from $25 to $20.

News

Price Target

Analyst Ratings

CTNM

Morgan Stanley Maintains Overweight on Contineum Therapeutics, Lowers Price Target to $20

JP Morgan analyst Richard Sunderland maintains Portland Gen Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) with a Neutral and lowers the price target from $46 to $45.

JP Morgan Maintains Neutral on Portland Gen Electric, Lowers Price Target to $45

Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) has received limited approval from the U.S. Food and Drug Administration for its COVID-19 vaccine, Nuvaxovid, marking a regulatory milestone and unlocking a <a href="https://www.benzinga.com/pressreleases/25/05/n45489838/u-s-fda-approves-bla-for-novavaxs-covid-19-vaccine" target="_blank" rel="noreferrer noopener">$175 million milestone payment</a> from partner Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).
The protein-based vaccine, distinct from mRNA options by Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), is now authorized for people aged 65 and older and for individuals 12 and up with underlying medical conditions that increase the risk of severe COVID-19. 
The approval came after a six-week delay as regulators sought additional data.
Related: <a href="https://www.benzinga.com/government/regulations/25/05/45488265/novavax-wins-limited-fda-nod-for-covid-shot-cleared-only-for-seniors-high-risk-groups-amid-safety-scrutiny" target="_blank" rel="noreferrer noopener">Novavax Wins Limited FDA Nod For COVID Shot—Cleared Only For Seniors, High-Risk Groups Amid Safety Scrutiny</a>         
Novavax CEO John C. Jacobs called the decision "a significant milestone" and emphasized the company's commitment to vulnerable populations. The CDC has noted that these groups will most likely seek seasonal COVID vaccinations.
The approval comes as CDC advisers weigh adjustments to annual COVID shot guidance, potentially narrowing recommendations to older adults and high-risk groups.
Novavax plans to begin commercial distribution of its 2025–2026 formula this fall, pending strain selection at the FDA advisory committee meeting on May 22. The company is also working with Sanofi to fund a Phase 4 study in adults 50–64 without high-risk conditions, as requested by the FDA.
Financially, Novavax reaffirmed its 2025 forecast for R&amp;D and SG&amp;A expenses between $475 million and $525 million. It plans to cut these to around $350 million in 2026 and $250 million by 2027, according to BZ Pro.
Related ETFs: iShares Biotechnology ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBB#NASDAQ">IBB</a>), SPDR S&amp;P Biotech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>)
Price Action: NVAX shares are trading higher by 19.0% at $8.01 premarket at the last check on Monday.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45495742/nvidia-unveils-ai-tools-for-humanoid-robots-launches-quantum-ai-supercomputer-to-drive-next-tech-era">Nvidia Unveils AI Tools For Humanoid Robots, Launches Quantum-AI Supercomputer To Drive Next Tech Era</a></li>
</ul>
Image: Shutterstock

BNTX

MRNA

NVAX

Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment

Morgan Stanley analyst Michael Phillips maintains Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) with a Equal-Weight and raises the price target from $280 to $300.

Morgan Stanley Maintains Equal-Weight on Chubb, Raises Price Target to $300

Benchmark analyst Mark Zgutowicz maintains Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) with a Buy and lowers the price target from $260 to $245.

Benchmark Maintains Buy on Wix.com, Lowers Price Target to $245

Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) showcased a new lineup of graphics processing units (GPUs) and AI accelerators designed for professionals and developers at <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45489409/computex-2025-intel-unveils-new-gpus-for-ai-and-workstations" rel="noreferrer noopener">the Computex 2025</a> on Monday.
Intel launched Arc Pro B60 and B50 graphics processing units for workstations and AI inference.
During the May 20-23 event in Taipei, Taiwan, Intel marks 40 years of collaboration with local ecosystem partners and expands its GPU lineup, AI accelerator capabilities, and AI assistant availability.
Also Read: <a href="https://www.benzinga.com/media/25/05/45456613/intel-cfo-says-new-chip-output-for-clients-will-be-minimal-eyes-foundry-breakeven-by-2027" target="_blank" rel="noreferrer noopener">Intel CFO Says New Chip Output For Clients Will Be Minimal, Eyes Foundry Breakeven By 2027</a>
Intel announces Intel&nbsp;Arc Pro B60 and Intel&nbsp;Arc Pro B50 GPUs, expanding the&nbsp;Intel&nbsp;Arc Pro family&nbsp;with configurations tailored for AI inference and professional workstations.
Intel&nbsp;Gaudi&nbsp;3 AI accelerators&nbsp;are now available in PCIe and rack-scale systems, offering scalable, open solutions for enterprise and cloud AI inferencing.
Now publicly available on GitHub,&nbsp;Intel&nbsp;AI Assistant Builder&nbsp;enables developers to create local, purpose-built AI agents optimized for Intel platforms.
This week&#8217;s product launches coincide with Intel&#8217;s 40th anniversary in Taiwan, which marks four decades of collaboration.
New Intel Arc Pro B60 and B50 GPUs based on the Xe2 architecture feature Intel&nbsp;Xe&nbsp;Matrix Extensions (XMX) AI cores and advanced ray tracing units, bringing high-performance capabilities to creators, developers, and engineers.
Expanding Intel&#8217;s GPU lineup for professionals, new Intel Arc Pro B60 and Intel Arc Pro B50 GPUs are designed for demanding AI inference workloads and workstation applications.
The GPUs are optimized for AEC (architecture, engineering, construction) and inference workstations, offering stability and performance through various independent software vendor (ISV) certifications and optimized software.
The Intel Arc Pro B-Series GPUs are compatible with consumer and pro drivers on Windows.
On Linux, the GPUs support a containerized software stack to simplify AI deployments and will be progressively upgraded with features and optimizations.
The Intel Arc Pro B-Series offers creators and AI developers scalable, cost-effective solutions by combining high memory capacity with key software compatibility.
Intel also revealed a configurable workstation-class Intel&nbsp;Xeon-based platform (code-named Project Battlematrix) designed to reduce friction points for AI developers.
It supports up to eight Intel Arc Pro B60 24GB GPUs to enable medium-size (up to 150 billion parameters) and accurate AI models with up to 192GB of video random-access memory.
Intel chief Lip-Bu Tan told Reuters on Monday that the company has a 55% share of the data center market.
Recently, Intel announced that <a href="https://www.benzinga.com/media/25/04/45079217/intel-ramps-up-new-chip-tech-to-take-on-taiwan-semiconductors-global-lead" target="_blank" rel="noreferrer noopener">several contract manufacturing</a> customers planned to&nbsp;build test chips&nbsp;for its forthcoming advanced manufacturing process as it struggles to win market share from Taiwan Semiconductor Manufacturing Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).
Price Actions: INTC stock is down 1.45% at $21.34 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/05/45384346/amd-launches-epyc-4005-chips-for-small-business-and-cloud" target="_blank" rel="noreferrer noopener">AMD Launches EPYC 4005 Chips For Small Business And Cloud</a></li>
</ul>
Photo: Tada Images/ Shutterstock.com

Tech

Media

INTC

Intel's Next-Gen AI Tech Steals The Show At Computex 2025

JP Morgan analyst Anne Samuel maintains IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) with a Overweight and lowers the price target from $232 to $177.

JP Morgan Maintains Overweight on IQVIA Hldgs, Lowers Price Target to $177

Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) with a Overweight and lowers the price target from $55 to $52.

CGON

Morgan Stanley Maintains Overweight on CG Oncology, Lowers Price Target to $52

Morgan Stanley analyst Nigel Dally maintains Brighthouse Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>) with a Underweight and raises the price target from $41 to $45.

Brighthouse Financial, Inc. - Common Stock

Morgan Stanley Maintains Underweight on Brighthouse Finl, Raises Price Target to $45

JP Morgan analyst Tien-Tsin Huang maintains Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) with a Overweight and lowers the price target from $211 to $210.

JP Morgan Maintains Overweight on Fiserv, Lowers Price Target to $210

Morgan Stanley analyst Bob Huang maintains Bowhead Specialty Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOW#NYSE">BOW</a>) with a Equal-Weight and raises the price target from $36 to $39.

Morgan Stanley Maintains Equal-Weight on Bowhead Specialty Hldgs, Raises Price Target to $39

JP Morgan analyst Jeremy Tonet maintains Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) with a Overweight and lowers the price target from $25 to $23.

JP Morgan Maintains Overweight on Energy Transfer, Lowers Price Target to $23

Fastenal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) has outperformed the market over the past 20 years by 4.77% on an annualized basis producing an average annual return of 13.08%. Currently, Fastenal has a market capitalization of $47.35 billion. 
Buying $1000 In FAST: If an investor had bought $1000 of FAST stock 20 years ago, it would be worth $11,745.80 today based on a price of $82.55 for FAST at the time of writing.
<h3>Fastenal's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747665013_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

FAST

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Benchmark analyst Mike Hickey reiterates Sphere Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHR#NYSE">SPHR</a>) with a Sell and maintains $35 price target.

Reiteration

SPHR

Benchmark Reiterates Sell on Sphere Entertainment, Maintains $35 Price Target

Morgan Stanley analyst Bob Huang maintains Assurant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>) with a Equal-Weight and raises the price target from $200 to $217.

Morgan Stanley Maintains Equal-Weight on Assurant, Raises Price Target to $217

Morgan Stanley analyst Michael Phillips maintains Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) with a Overweight and raises the price target from $105 to $110.

ACGL

Morgan Stanley Maintains Overweight on Arch Capital Group, Raises Price Target to $110

Benchmark analyst Mike Hickey reiterates PENN Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) from Hold to Hold.

PENN

Benchmark Reiterates Hold on PENN Entertainmentto Hold

JP Morgan analyst Richard Sunderland maintains Edison Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>) with a Neutral and lowers the price target from $75 to $71.

JP Morgan Maintains Neutral on Edison Intl, Lowers Price Target to $71

Morgan Stanley analyst Adam Jonas maintains Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) with a Underweight and lowers the price target from $60 to $55.

APTV

Morgan Stanley Maintains Underweight on Aptiv, Lowers Price Target to $55

Morgan Stanley analyst Michael Phillips maintains American International Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) with a Equal-Weight and raises the price target from $81 to $85.

Morgan Stanley Maintains Equal-Weight on American International Gr, Raises Price Target to $85

Press Releases

GrabAGun Nominates Donald Trump Jr. and Post-Closing Board of Directors and Advances Plans for Upcoming Public Listing

PublicSquare to Present at the Emerging Growth Conference

Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

PublicSquare's PSQ Payments Comes to the Rescue for Tenacity Arms After Sudden Cancellation by Leading Payment Processor

PSQ Payments Launches Direct Integration with Shopify, Expanding Cancel-Proof Payment Solutions to America's Leading E-Commerce Platform

PublicSquare Announces First Quarter 2025 Financial Results Release Date & Conference Call

Updated GrabAGun Filing Identifies Additional Director Nominees to Join Donald Trump Jr. on Planned GrabAGun Board

PublicSquare Announces First Marketplace Merchant to Successfully Migrate to PSQ Payments: Yonder Integrates Directly via Shopify

PublicSquare Reports First Quarter 2025 Financial Results

ASBP

BENF

BIXT

BNZI

CLBR

CLNN

CSE:HG

CUAUF

CYIO

ELRRF

EVFM

GOVX

HGRAF

OMEX

OPWEF

PSQH

RGBP

SEVCF

TSX:ELO

TSX:URE

TSXV:CCCM

TSXV:OPW

TSXV:UCU

USEG

UURAF

XXII

The Arena Group Holdings, Inc. Common Stock

Arena Group Holdings

Bumble

BuzzFeed

Cheer Holding, Inc. - Class A Ordinary Share

Cheer Holding

DHI Group

Fangdd Network Group Ltd. - Class A Ordinary Shares

Fangdd Network Group

Phoenix New Media Limited American Depositary Shares, each representing 48 Class A ordinary shares.

Phoenix New Media

Giftify

Intelligent Protection Management Corp. - Common Stock

Intelligent Protection

IZEA Worldwide

Nextdoor Holdings, Inc. Class A Common Stock

Nextdoor Holdings

MediaAlpha

MoneyHero Limited - Class A Ordinary Shares

MoneyHero

Outbrain

Oriental Culture Holding LTD - Ordinary Shares

Oriental Culture Holding

System1

So-Young International Inc. - American Depository Shares

So-Young Intl

TrueCar

trivago N.V. - American Depositary Shares

trivago

Travelzoo

Zedge

Zhihu Inc. American Depositary Shares, each representing three (3) Class A Ordinary Shares

Comments

PSQ Holdings

空売り

PSQ Holdings (NYSE:PSQH) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル